BioSpace News Archive

Health Logic Interactive Inc. (“Health Logic” or the “Company”) (NEX: CHIP), is pleased to announce the hiring of Mr. David Barthel, as the Chief Executive Officer for Health Logic.

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020.

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announces that it is changing its fiscal year-end to December 31, from its current fiscal year-end of April 30. The notice for the year-end change required under National Instrument 51-102 has been filed under the Company’s profile at www.sedar.com.

InnovAge Holding Corp. (Nasdaq: INNV) today announced that on March 9, 2021, the underwriters of the previously announced initial public offering of 16,666,667 shares of its common stock exercised their option to purchase an additional 2,329,234 shares of common stock from InnovAge at the initial public offering price of $21.00 per share, less underwriting discounts and commissions

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, announces that two of its long-standing directors have announced their intention to retire from the Board.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020 .

Seres Therapeutics to Present at the 31 st Annual Oppenheimer Healthcare Conference

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA ® (tivozanib) in Combination with OPDIVO ® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma

Agreement provides exclusive rights to all available data included in the original new drug application for mazindol in the U.S.